Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients (Q34631665)

3 August 2017

1 reference

title

Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients (English)

1 reference

3 August 2017

1 reference

Ronald Mitsuyasu

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

Journal of Infectious Diseases

3 August 2017

published in

1 reference

3 August 2017

volume

185 Suppl 2

1 reference

3 August 2017

page(s)

S115-22

1 reference

Immune Reconstitution Strategies in HIV.

3 August 2017

cites work

1 reference

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

21 January 2018

1 reference

Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

21 January 2018

1 reference

Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults

21 January 2018

1 reference

Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.

21 January 2018

1 reference

Highly active antiretroviral therapy (HAART) and circulating markers of immune activation: specific effect of HAART on neopterin

21 January 2018

1 reference

Immune restoration with antiretroviral therapies: implications for clinical management

21 January 2018

1 reference

Immune control of HIV-1 after early treatment of acute infection

21 January 2018

1 reference

Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir

21 January 2018

1 reference

Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir

21 January 2018

1 reference

Human immunodeficiency virus type 1 envelope-stimulated interleukin-2 production and survival of infected children with severe and mild clinical disease

21 January 2018

1 reference

Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression

21 January 2018

1 reference

Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patients

21 January 2018

1 reference

Low-dose daily interleukin-2 immunotherapy: accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicity

21 January 2018

1 reference

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

21 January 2018

1 reference

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection

21 January 2018

1 reference

Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.

21 January 2018

1 reference

Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients

21 January 2018

1 reference

Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy

21 January 2018

1 reference

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy

21 January 2018

1 reference

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

21 January 2018

1 reference

Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load

21 January 2018

1 reference

Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease

21 January 2018

1 reference

Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.

21 January 2018

1 reference

Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report

21 January 2018

1 reference

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

21 January 2018

1 reference

A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research

21 January 2018

1 reference

Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.

21 January 2018

1 reference

DNA vaccination for HIV-1 and SIV.

21 January 2018

1 reference

Interleukin-12 enhancement of antigen-specific lymphocyte proliferation correlates with stage of human immunodeficiency virus infection

21 January 2018

1 reference

Interleukin (IL)-15 enhances antibody-dependent cellular cytotoxicity and natural killer activity in neonatal cells

21 January 2018

1 reference

Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediate

21 January 2018

1 reference

IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine

21 January 2018

1 reference

Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1.

21 January 2018

1 reference

Potential nuclease-based strategies for HIV gene therapy

21 January 2018

1 reference

Current developments and future prospects for HIV gene therapy using interfering RNA-based strategies

21 January 2018

1 reference

Hematologic recovery in mice transplanted with bone marrow stem cells expressing anti-human immunodeficiency virus genes

21 January 2018

1 reference

Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/340201

1 reference

3 August 2017

1 reference